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Background: Amyloidoses are a heterogeneous group of progressive diseases caused by tissue deposition of
misfolded proteins. According to the International Classification of Diseases, hereditary amyloidosis is divided into
neuropathic and non-neuropathic forms. In Sweden, neuropathic heredofamilial amyloidosis has been identified
as familial amyloidotic polyneuropathy (FAP), a fatal disease that is treated by liver transplantation. The
non-neuropathic form includes familial autoinflammatory diseases. As no incidence data on these hereditary
diseases are available and as even diagnostic data on non-neuropathic forms are lacking we determined the
incidence of these diseases and characterized non-neuropathic conditions.
Methods: Patients were identified using data from the Swedish Hospital Discharge Register and from the
Outpatient Register for 2001 through 2008. All patients discharged with hereditary amyloidosis diagnoses were
included and standardized incidence rates were calculated.
Results: Non-neuropathic disease was diagnosed in 210 patients, with an incidence of 2.83 per million. FAP was
diagnosed in 221 patients, with an incidence of 2.02 per million. Two northern provinces that are home to 5% of
the Swedish population accounted for 77% of FAP cases; the incidence in one of them, West Bothnia, was 100
times that in the rest of Sweden. Approximately 98% of non-neuropathic disease patients were immigrants, most
of whom were from the Eastern Mediterranean area. Young Syrian descendants had the highest incidence rate,
which was over 500-fold higher than that in individuals with Swedish parents. Even the early onset of these
conditions identified them as familial autoinflammatory diseases.
Conclusions: FAP cases were highly concentrated in the two northernmost provinces. Non-neuropathic familial
autoinflammatory diseases were of early-onset and immigrant origin most likely related to periodic fever
syndromes. Paradoxically, FAP has remained endemic, in spite of population movements within the country,
while familial autoinflammatory diseases, with an incidence exceeding that of FAP, were brought into the
country as a result of immigration mainly from the Eastern Mediterranean area.
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Amyloidosis is a heterogeneous group of diseases char-
acterized by fibrillar protein deposits called amyloids in
a single organ or multiple organs [1]. The disease no-
menclature is based on the precursors of the amyloid
fibrils for which at least 28 different proteins have been
identified [1,2]. Amyloidosis presents in sporadic and
familial forms, but incidence or prevalence data are
largely lacking for all forms of the disease [3,4]. The
most common and widespread form of hereditary
amyloidosis is familial amyloidotic polyneuropathy (FAP),
which is caused by transthyretin mutations leading to
amyloid accumulation in critical organs and tissues,
such as peripheral nerves, the digestive tract, the heart,
and the kidneys [5,6]. The prevalence of this dominantly
inherited amyloidosis is highest in Portugal, Sweden
and Japan. Case numbers show large regional differences
and the penetrance varies by mutation type and geography
[7]. FAP is a progressive fatal disease that can be alleviated
through liver transplantation, as the liver is the site of
transthyretin synthesis [8]. FAP liver transplantations are
carried out on a worldwide basis, and are coordinated
by The Familial Amyloidotic Polyneuropathy World
Transplant Registry (http://www.fapwtr.org) [9]. As of
the end of 2010, 1,900 FAP transplantations had been
performed. Other dominant hereditary forms of amyloid-
osis include apolipoprotein AI- and II-, gelsolin-, cystatin
C-, lysozyme-, and fibrinogen A-related diseases, all of
which are extremely rare and have relatively early onset
and distinct geographical locations [5,6]. Fibrinogen A
is reported to be the most common type of hereditary
renal amyloidosis [10]. There are no data on hereditary
amyloidosis other than FAP in Sweden, except that an
expert review stated that gelsolin and apolipoprotein-
related familial patients have been identified [11].
Reactive amyloidosis is a systemic form of the disease
in which serum acute phase protein, amyloid A is the
amyloid precursor. Reactive amyloidosis occurs as a
secondary condition in patients with chronic inflammation
or cancer. Many rheumatoid arthritis patients are diag-
nosed with reactive amyloidosis during the course of
their disease [12]. Periodic fever syndromes and other
inflammasome-related autoinflammatory conditions may
also cause reactive amyloidosis [13-16]. Even though
reactive amyloidosis may not be familial, it is a clinical
manifestation of hereditary periodic fever syndromes
which include pyrin-associated familial Mediterranean
fever (FMF), cryopyrin-associated periodic syndrome,
mevalonate kinase deficiency, and tumor necrosis factor
receptor-associated periodic syndrome [13]. FMF is
common in the Eastern Mediterranean area but rare
elsewhere, as are the other periodic fever syndromes. A
European registry on autoinflammatory diseases included
1049 patients with monogenic diseases but it reportedonly one patient in Sweden [17]. These diseases are
normally diagnosed before age 20 years; the kidneys
and the gastrointestinal tract are the vulnerable organs
when the patients have developed amyloidosis [2,7,13].
According to the 10th revision of the International
Classification of Diseases, hereditary autoinflammatory
diseases are classified together with hereditary renal
amyloidosis as ‘non-neuropathic heredofamilial amyloid-
osis‘, code E85.0. However, the development of amyl-
oidosis in hereditary autoinflammatory disease patients
depends on the severity of the condition and may be
rare in patients responding to treatment, which for
FMF includes colchicine [6,18,19]. Thus code E85.0
does not distinguish between patients with or without
amyloidosis.
In this paper we addressed the lack of incidence data
on these hereditary diseases using nationwide hospital
discharge and outpatient data from Sweden for 2001
through 2008. The results showed that the patient char-
acteristics for ‘non-neuropathic heredofamilial amy-
loidosis‘, code E85.0 showed identity with hereditary
autoinflammatory diseases and we use this disease des-
ignation in the following text. There was no evidence
for patients with hereditary renal amyloidosis which
would also be covered by code E.85.0. In agreement, a
Swedish review of 1000 consecutive kidney transplant
patients revealed 189 ‘clear’ hereditary renal disorders
but none were hereditary renal amyloidosis; the two
amyloidosis patients belonged to a FAP pedigree from
Northern Sweden [20]. The data also suggested that
‘neuropathic heredofamilial amyloidosis‘ patients (code
E85.1) suffered from FAP and we use this term in the
text. The results were unexpected, FAP remains a local
endemic disease and hereditary autoinflammatory diseases
were imported by immigrants, which reiterates the
importance of international health. Some 15% of the
Swedish population is born outside Sweden [21].Methods
Data sources
Amyloidosis patients were identified using the Swedish
Hospital Discharge Register (2001–2008) and the Out-
patient Register (2001–2008). The Hospital Discharge
Register has had nationwide coverage since 1987 and
regional coverage since 1964. In order to ensure that
the reported incidence data only included newly diagnosed
cases, anyone who had been diagnosed with amyloidosis
prior to 2001 was excluded. Information from the registers
was linked at the individual level via the national 10-digit
civic registration number assigned to each resident in
Sweden for his or her lifetime. In the linked dataset, civic
registration numbers were replaced with serial numbers to
ensure the anonymity of all individuals.
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of Diseases was used to identify disease cases using the
following diagnostic codes: E85.0 for hereditary auto-
inflammatory disease, E85.1 for FAP and E85.2 for
unspecified heredofamilial amyloidosis. Although amyl-
oidosis diagnosis should be based on the demonstration
of amyloid fibrils in tissue biopsies, it is likely that for
diagnostic group E85.0, the periodic fever symptoms
rather than demonstration of amyloidosis fibrils were
the bases of diagnoses. The reason is the ambiguous as-
signment of hereditary autoinflammatory disease into
this amyloidosis code. On the other hand, FAP should
be correctly diagnosed and the types of transthyretin
mutations are largely known in the pedigrees [7].Individual-level variables
Sex: Males or females. Geographic region of residence
was divided into: (1) large cities (cities with a population
of more than 200,000, i.e., Stockholm, Gothenburg, and
Malmö); (2) Southern Sweden; and (3) Northern Sweden.
Sweden is divided into 25 provinces. The border between
Northern and Southern Sweden has traditionally been
drawn at Dalälven (the Dal River, north of Stockholm),
which we used to define the geographic boundary between
Southern and Northern Sweden. The dataset included
information on people from 64 countries and regions
of birth according to the available classification.Statistical analysis
Person-years were calculated from the start of follow-up
on 1 January 2001 until diagnosis of the relevant disease,
death, emigration, or the end of the study (31 December
2008). All hereditary diseases, newly diagnosed during
the follow-up period, were considered, irrespective of
their possible kinship. In order to guarantee that the
patients were newly diagnosed, anyone hospitalized
prior to 2001 with a related diagnosis were excluded.
Age-, gender-, region of residence-, immigration status-,
and diagnosis subtype-specific incidence rates were cal-
culated for the whole follow-up period. Relative weights
used to calculate incidence rates were based on the
European Standard Population for 2000. We used SAS
version 9.2 for the statistical analyses.Table 1 Case numbers and incidence rates (per million person
Men
Subtype (ICD-10 code) No. IR 95%
Hereditary autoinflammatory disease (E85.0) 116 3.11 2.54
Familial amyloidotic polyneuropathy (FAP, E85.1) 138 2.35 1.95
Heredofamilial amyloidosis, unspecified (E85.2) 15 0.25 0.13Ethical considerations
This study was approved by the Ethics Committee of
Lund University, Sweden. All data were anonymous and
no informed consents could be obtained.Results
Numbers of cases and incidence rates for the hereditary
diseases are shown in Table 1 for period 2001 to 2008.
Hereditary autoinflammatory disease was diagnosed in
210 patients, with a standardized incidence rate of 2.83
per million. FAP was diagnosed in 221 patients with an
incidence rate of 2.02 per million after standardization.
The rate was 1.8-fold higher in males than in females.
Unspecified heredofamilial amyloidosis was rare; only 30
patients were diagnosed with this condition during the
study period (standardized incidence rate 0.26 per
million). In period 2001–2008, 68% of the patients with
hereditary autoinflammatory disease were treated two
or more times with the same diagnosis; for FAP the
percentage was 73 and for unspecified heredofamilial
amyloidosis it was 63. We wanted to characterize better
unspecified heredofamilial amyloidosis by finding out if
patients with this diagnosis were subsequently discharged
with another related diagnosis. Among the 30 patients in
Table 1, one was subsequently discharged with diagnosis
FAP. Among patients diagnosed between 1997 and 2001
and not included in Table 1, 27 patients were diagnosed
with unspecified heredofamilial amyloidosis and 10 of
them were later diagnosed with FAP.
Age-specific incidence rates for the diseases are shown
in Figure 1. The incidence of hereditary autoinflammatory
disease peaked at age 30 to 39 years (median age at
diagnosis 32 years) in males and 20 to 29 years (median
age at diagnosis 29 years) in females Figure 1A. The
incidence of FAP peaked sharply in men at age 70 to
79 years (median age at diagnosis 67 years) and less
sharply in women 10 years earlier (median age at diag-
nosis 57 years) (Figure 1B). Unspecific heredofamilial
amyloidosis was also found to be a disease of old age;
the median age at diagnosis was 66 years for men and
64 years for women (Figure 1C).
Differences in the incidence of these diseases according
to region of residence in 1990 are shown in Table 2.
Data for regions where the incidence was more thanyears) for hereditary diseases in Sweden, 2001-2008
Women All
CI No. IR 95% CI No. IR 95% CI
3.68 94 2.54 2.03 3.06 210 2.83 2.45 3.22
2.74 83 1.70 1.33 2.07 221 2.02 1.76 2.29
0.38 15 0.27 0.13 0.40 30 0.26 0.17 0.35




Figure 1 Age-specific incidence rates (per million person-years) for amyloidosis by subtype (1997-2008). (A) Hereditary autoinflammatory
disease (E85.0). (B) Familial amyloidotic polyneuropathy (FAP, E85.1). (C) Heredofamilial amyloidosis, unspecified (E85.2).
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No. IR 95% CI No. IR 95% CI No. IR 95% CI
Jönköping 4 0.92 0.02 1.81
Västerbotten (West Bothnia) 122 45.28 37.25 53.32 4 1.29 0.03 2.55
Norrbotten (North Bothnia) 49 13.16 9.48 16.85
Unspecified 102 7.96 6.42 9.51
All 210 2.83 2.45 3.22 221 2.02 1.76 2.29 30 0.26 0.17 0.35
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hereditary autoinflammatory disease, none of the 25
provinces showed an increase because close to half of
patients resided in an ‘unspecified residential area’. The
only significant differences in incidence rates compared
with the overall incidence in Sweden for FAP were for
Västerbotten (West Bothnia) and Norrbotten (North
Bothnia); for unspecified heredofamilial amyloidosis,
Västerbotten showed a non-significant difference from
the overall incidence in Sweden. These two provinces
are located in the most northern part of Sweden. North
Bothnia is the northernmost province and West Bothnia
borders it to the south. Remarkably, the two provinces
together accounted for 77% of FAP cases in Sweden.
The incidence of FAP in West Bothnia was 22 times
higher than the national average. Moreover, as the inci-
dence outside West Bothnia and North Bothnia was only
0.45 per million (N = 50, 95% CI 0.33-0.57); the incidence
in West Bothnia of 45.28 per million was 100 times higher
than that in the rest of the country.
A large proportion of patients with hereditary autoin-
flammatory disease had unspecified residential area in
1990, and we suspected that the reason was that some of
them were immigrants. Table 3 shows the country of birth
for patients diagnosed with hereditary autoinflammatory
disease. More than half of the patients were foreign-
born, with immigrants from Turkey, Lebanon and SyriaTable 3 Case number and incidence rates (per million person
country of the first generation
First generation
Birth country No. IR 95% CI
Sweden 95 1.48 1.18 1.7
Turkey 20 50.17 28.18 72
Libanon 22 74.70 43.48 10
Iran 12 35.40 15.37 55
Syria 20 109.40 61.45 15
The United Arab Emirates 5 59.90 7.40 11
Armenia/Azerbaijan/Georgia* 5 44.90 5.54 84
All 210 2.83 2.45 3.2
Countries included when at least 3 patients in the first generation had immigrated.
*Additional countries: Kazachstan/Kirgizistan/Tadzjikistan/Turkmenistan/Ukraine/Uzbconstituting the largest groups (each contributing 20 or
more patients). Syrians had the highest incidence rate
(109.40 per million). All the listed nationalities had sig-
nificantly higher incidence rates compared to Swedes.
A closer look at the 95 Swedish-born individuals
showed that both parents of only 9 of them were born in
Sweden; however, the ethnicity of these parents could
not be confirmed. The incidence of hereditary autoin-
flammatory disease in Swedish-born individuals whose
parents were both born in Sweden was 0.25 per million.
Among the second-generation immigrants with com-
patriot parents, those of Syrian descendent showed the
highest incidence (136 per million, i.e., over 500 times
higher than the incidence in individuals with two
Swedish-born parents). There were too few cases to
draw conclusions about differences in incidence rates
between first- and second-generation immigrants.
Age-specific incidence rates for second generation
immigrants of Turkish, Lebanese and Syrian descent
are shown in Figure 2. The incidence for both genders
combined peaked at age 20 to 29 years. The median age
at diagnosis for both genders combined was 14 years
(11 years for males, 19 years for females).
Discussion
The advantages of the present study include nationwide
coverage in a country with universal access to medicalyears) for hereditary autoinflammatory disease by birth
Second generation of compatriot parents
No. IR 95% CI
8 9 0.25 0.09 0.41
.16 14 38.10 18.14 58.06
5.92 11 99.40 40.66 158.14
.43 5 12.60 1.56 23.64
7.35 15 136.40 67.37 205.43




Age at diagnosis (years)
Figure 2 Age-specific incidence rates (per million person-years) for hereditary autoinflammatory disease (E85.0) among
second-generation immigrants with compatriot parents from Turkey, Lebanon, and Syria (based on 22 males, 18 females).
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nostics are time-consuming and it has been reported
that a small proportion of hereditary amyloidosis is
misdiagnosed as the common immunoglobulin light
chain amyloidosis [22]. However, FAP is well known in
Sweden and, moreover, two thirds of the patients were
discharged more than once with the same specific
amyloidosis subtype which implies consistent diagnostics.
Also, the striking finding showing the precise geographic
location of FAP cases and the immigrant dominance of
hereditary autoinflammatory disease testify to a high
diagnostic accuracy. Based on the similar geographic
location, approximately similar age distribution and
interchanged diagnosis in many patients of FAP and
unspecified heredofamilial amyloidosis, they may be the
same disease, with a joint incidence of 2.28 per million,
somewhat less than that of hereditary autoinflammatory
disease (2.83 per million). These incidence rates refer to
inpatients and outpatients for years 2001 to 2008.
Swedish neuropathic heredofamilial amyloidosis (FAP) is
caused by any of three identified transthyretin mutations.
However, even for the same mutation penetrance and
manifestations vary [7]. The mean age of onset has been
reported to be 56 years, which is somewhat lower than
what we found here (the median age at diagnosis was
67 years for men and 57 years for women). The likely
explanation is that symptoms do not immediately lead
to hospitalization, but once patients are hospitalized
amyloidosis is fulminant. However, considering the vari-
able penetrance of FAP, the present incidence rates under-
estimate the incidence of FAP. Our data showed that 77%
of the Swedish FAP patients were diagnosed in the two
northernmost provinces of Sweden (West and NorthBothnia), which together account for slightly more than
5% of the Swedish population. The incidence of FAP
was over 100-fold higher in West Bothnia than in the
rest of the country (excluding North Bothnia), in spite of
large population movements within Sweden since the
Second World War.
Autoinflammatory diseases are caused by dysfunction
of the inflammasome complex of the innate immune
system [13,14]. They include several monogenic diseases
such as pyrin-associated FMF, cryopyrin-associated peri-
odic syndrome, mevalonate kinase deficiency, and tumor
necrosis factor receptor-associated periodic syndrome.
Many of these diseases are diagnosed by pediatricians
and, for example, 80% of FMF cases occur before age
20 years [13]. FMF is, according to a review, almost
always restricted to Turks, Armenians, Arabs and non-
Ashkenazi Jews or emigrants with these ethnicities and,
according to this source, no cases have been described in
individuals of Scandinavian origin [18]. Autoinflammatory
conditions may give rise to reactive amyloidosis, which
may manifest initially as renal problems; the amyloid
precursor is serum amyloid A, the normal and not a
mutated protein [13-16,18]. Our first clue that code
E85.0 included periodic fever syndromes was the over-
whelming proportion of patients who were immigrants
from the Eastern Mediterranean area, with the incidence
being highest in first-generation Syrian immigrants (109
per million) and their descendants (136 per million). In
endemic areas, rates have been estimated to be as high
as 1,000 per million [18]. The relatively early age of onset
also supported the disease identity of periodic fever
syndrome; the highest incidence rates were in the 20 to
29 years age group in second-generation immigrants
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important to note that the immigrant populations ori-
ginating from the Eastern Mediterranean area are rela-
tive newcomers to Sweden and their oldest descendants are
still young adults [23]. Thus, the calculated median
ages at hospitalization are likely to be too high in the
first generation immigrants who entered Sweden at
around age 25 years and who could have the disease
already at immigration. The delay between first disease
episodes and diagnosis was over 7 years in the Eurofever
registry [17]. The calculated median ages may be too
low for the young second generation because of the age
truncation (still a young population).
An obvious question resulting from the above findings
is whether native Swedes have indigenous hereditary
autoinflammatory or related diseases. Among the 210
identified patients, 95 were born in Sweden but for only
nine (2.3%) had both parents been born in Sweden.
However, we were unable to confirm parental ethnicity.
Recent data demonstrated that some inflammasome-
related conditions appear to have indigenous origins in
Sweden. Cryopyrin-associated periodic syndrome cases
diagnosed in adulthood have been reported and common
inflammasome-related NLRP3 and CARD8 polymorphisms
have been described, although without evidence on disease
susceptibility [15,16]. Cases of pediatric periodic fever,
aphthous stomatitis, pharyngitis and adenitis (PFAPA)
have also been described in Sweden, but the disease is
apparently not heritable; mevalonate kinase deficiency
has not been diagnosed in ethnic Swedes [24]. Taken
together, the available data suggest that hereditary auto-
inflammatory disease, as described in the present study, is
a disease of immigrants originating from the Eastern
Mediterranean area.
Conclusions
In conclusion, this nationwide hospital in- and outpatient
study showed an incidence of 2.02 per million for FAP
and 2.83 per million for hereditary autoinflammatory
disease. Both of these diseases showed distinct charac-
teristics. FAP cases were concentrated in the two
northernmost provinces of Sweden, suggesting that this
disease entity only constitutes FAP with transthyretin
mutations and practically excluding other types of dis-
eases. Hereditary autoinflammatory disease was found
to be an early-onset disease of immigrant origin. However,
the identities of the type(s) of periodic fevers could not
be established. Paradoxically, FAP has remained endemic,
in spite of population movements, while hereditary auto-
inflammatory disease has been brought into the country
as a result of population movements. We have recently
shown that Swedish FAP patients have an increased risk of
non-Hodgkin lymphoma (Hemminki et al. unpublished
observation).Abbreviations
FAP: Familial amyloidotic polyneuropathy; IR: Incidence rate; CI:
Confidence interval.
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